

**EDITORIAL**

# Cannabinoids and their actions: An update

**LINKED ARTICLES**

This article is part of a themed section on 8<sup>th</sup> European Workshop on Cannabinoid Research. To view the other articles in this section visit <http://onlinelibrary.wiley.com/doi/10.1111/bph.v176.10/issuetoc>

The first themed issue on Cannabinoids Editorial (Alexander & Randall, 2007) discussed why ... why the themed issue, why the topic, and why *BJP*? The responses to these three questions are largely unchanged. A themed issue is a ready focus for authors and readers. The 2007 themed issue was based around the 3rd European Workshop on Cannabinoid Research and provided a rich source of both reviews and research papers. *BJP* has always championed cannabinoid research with numerous high-quality examples of research and scholarship to which to point. The 8th European Workshop on Cannabinoid Research took place in Roehampton, West London, in August/September 2017. It involved speakers from four continents and gave rise to the review articles and research papers presented in this themed issue.

The review articles underline the breadth of action of cannabinoids/endocannabinoids, encompassing examples of cell determination (Garcia-Arencibia, Molina-Holgado, & Molina-Holgado, 2019) to cell death (Fernandez-Ruiz, 2019). There are reviews on more translational aspects of cannabinoids. Burkhard Hinz and Robert Ramer describe anti-tumour actions of cannabinoids (Hinz & Ramer, 2019), while Barbara Malinowska and colleagues look at the mechanisms of action and potential therapeutic significance of cannabinoids in different aspects of hypertension (Malinowska, Toczek, Pedzinska-Betiuk, & Schlicker, 2019). Kasia Starowicz (Malek & Starowicz, 2019) and Dave Finn (Okine, Gaspar, & Finn, 2019), with their respective colleagues, describe aspects of cannabinoids in joint repair problems and targetting non-canonical pathways in pain. In between, Harald Hansen and Vana Vasiliki describe the variation and potential influences of endocannabinoid-like compounds in the intestine (Hansen & Vana, 2019).

The research papers in this themed issue focus on the broad spectrum of cannabinoid actions. For example, the fundamentals of cannabidiol analogue action at **CB<sub>1</sub>** and **CB<sub>2</sub> receptors** are investigated by Rob Laprairie and colleagues (Tham et al., 2019), inflammatory

signalling changes in endocannabinoids in a colon cancer cell line from Chris Fowler and colleagues (Alhouayek, Rankin, Gouveia-Figueira, & Fowler, 2019), while a preliminary characterisation of a novel CB<sub>2</sub> receptor agonist PET ligand is described by Guy Bormans and colleagues (Attili et al., 2019).

The rest of the research papers look at cannabinoids in animal models with diverse elements of a CNS focus. Thus, one paper focusses on prefrontal cortex regulation of pain (Rea, McGowan, Corcoran, Roche, & Finn, 2019), while another looks at species differences in cannabinoid-induced convulsions (Whalley et al., 2019), and a third investigates endocannabinoid regulation of feeding (Sticht et al., 2019). Two papers look at features of reward and dependency: One looks at the roles of CB<sub>1</sub> and CB<sub>2</sub> receptors on behavioural responses to cocaine (Gobira et al., 2019). The second looks at **cannabidiol**, a non-euphoric plant cannabinoid and its effects on cognition and withdrawal to **Δ<sup>9</sup>-tetrahydrocannabinol (THC)**, the classical euphoric plant cannabinoid (Myers, Siegle, Foss, Tuma, & Ward, 2019). The two remaining papers look at different aspects of muscular and neurodegeneration: One focusses on non-euphoric plant cannabinoids in an mdx mouse dystrophic model (Iannotti et al., 2019), while the second looks at astroglial CB<sub>2</sub> receptor regulation of a mouse model of ALS (Espejo-Porras et al., 2019).

Overall, this themed issue underlines the diversity and translatability of cannabinoids. Furthermore, it underlines that despite the human multimillennial history of exploitation of the *Cannabis* plant, we are still learning a great deal about the compounds from the plant and the endogenous cannabinoid system which the plant has allowed us to identify.

We suspect this will not be the last themed issue on cannabinoids in the *British Journal of Pharmacology*, and we look forward to the next edition with some anticipation.

## CONFLICT OF INTEREST

The authors declare no conflicts of interest.

Stephen P. H. Alexander<sup>1</sup>  
Francisco Molina-Holgado<sup>2</sup>

<sup>1</sup>School of Life Sciences, University of Nottingham, Nottingham, UK

<sup>2</sup>Neural Stem Cell Laboratory, University of Roehampton, London, UK

### Correspondence

Stephen Alexander, School of Life Sciences, University of Nottingham Medical School, Nottingham NG7 2UH, UK  
Email: steve.alexander@nottingham.ac.uk

## REFERENCES

- Alexander, S. P. H., & Randall, M. (2007). Cannabinoids and their actions. *British Journal of Pharmacology*, 152, 557–558.
- Alhouayek, M., Rankin, L., Gouveia-Figueira, S., & Fowler, C. J. (2019). Interferon  $\gamma$  treatment increases endocannabinoid and related N-acylethanolamine levels in T84 human colon carcinoma cells. *British Journal of Pharmacology*, 176, 1470–1480.
- Attili, B., Celen, S., Ahamed, M., Koole, M., Haute, C. V. D., Vanduffel, W., & Bormans, G. (2019). Preclinical evaluation of [<sup>18</sup>F]MA3, a CB<sub>2</sub> receptor agonist radiotracer for PET. *British Journal of Pharmacology*, 176, 1481–1491.
- Espejo-Porras, F., Garcia-Toscano, L., Rodriguez-Cueto, C., Santos-Garcia, I., de Lago, E., & Fernandez-Ruiz, J. (2019). Targeting glial cannabinoid CB<sub>2</sub> receptors to delay the progression of the pathological phenotype in TDP-43 (A315T) transgenic mice, a model of amyotrophic lateral sclerosis. *British Journal of Pharmacology*, 176, 1585–1600.
- Fernandez-Ruiz, J. (2019). The biomedical challenge of neurodegenerative disorders: an opportunity for cannabinoid-based therapies to improve on the poor current therapeutic outcomes. *British Journal of Pharmacology*, 176, 1370–1383.
- Garcia-Arencibia, M., Molina-Holgado, E., & Molina-Holgado, F. (2019). Effect of endocannabinoid signalling on cell fate: life, death, differentiation and proliferation of brain cells. *British Journal of Pharmacology*, 176, 1361–1369.
- Gobira, P. H., Oliveira, A. C., Gomes, J. S., da Silveira, V. T., Asth, L., Bastos, J. R., ... Moreira, F. A. (2019). Opposing roles of CB<sub>1</sub> and CB<sub>2</sub> cannabinoid receptors in the stimulant and rewarding effects of cocaine. *British Journal of Pharmacology*, 176, 1541–1551.
- Hansen, H. S., & Vana, V. (2019). Non-endocannabinoid N-acylethanolamines and 2-monoacylglycerols in the intestine. *British Journal of Pharmacology*, 176, 1443–1454.
- Hinz, B., & Ramer, R. (2019). Anti-tumour actions of cannabinoids. *British Journal of Pharmacology*, 176, 1384–1394.
- Iannotti, F. A., Pagano, E., Moriello, A. S., Alvino, F. G., Sorrentino, N. C., D'Orsi, L., ... di Marzo, V. (2019). Effects of non-euphoric plant cannabinoids on muscle quality and performance of dystrophic mdx mice. *British Journal of Pharmacology*, 176, 1568–1584.
- Malek, N., & Starowicz, K. (2019). Joint problems arising from lack of repair mechanisms: can cannabinoids help? *British Journal of Pharmacology*, 176, 1412–1420.
- Malinowska, B., Toczek, M., Pedzinska-Betiuk, A., & Schlicker, E. (2019). Cannabinoids in arterial, pulmonary and portal hypertension - mechanisms of action and potential therapeutic significance. *British Journal of Pharmacology*, 176, 1395–1411.
- Myers, A. M., Siegele, P. B., Foss, J. D., Tuma, R. F., & Ward, S. J. (2019). Single and combined effects of plant-derived and synthetic cannabinoids on cognition and cannabinoid-associated withdrawal signs in mice. *British Journal of Pharmacology*, 176, 1552–1567.
- Okine, B. N., Gaspar, J. C., & Finn, D. P. (2019). PPARs and pain. *British Journal of Pharmacology*, 176, 1421–1442.
- Rea, K., McGowan, F., Corcoran, L., Roche, M., & Finn, D. P. (2019). The prefrontal cortical endocannabinoid system modulates fear-pain interactions in a subregion-specific manner. *British Journal of Pharmacology*, 176, 1492–1505.
- Sticht, M. A., Lau, D. J., Keenan, C. M., Cavin, J.-B., Morena, M., Vemuri, V. K., ... Hill, M. N. (2019). Endocannabinoid regulation of homeostatic feeding and stress-induced alterations in food intake in male rats. *British Journal of Pharmacology*, 176, 1524–1540.
- Tham, M., Yilmaz, O., Alaverdashvili, M., Kelly, M. E. M., Denovan-Wright, E. M., & Laprairie, R. B. (2019). Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors. *British Journal of Pharmacology*, 176, 1455–1469.
- Whalley, B. J., Lin, H., Bell, L., Hill, T., Patel, A., Gray, R. A., ... Stephens, G. J. (2019). Species-specific susceptibility to cannabis-induced convulsions. *British Journal of Pharmacology*, 176, 1506–1523.